Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current


AVITA Medical Revises FY23 Revenue Guidance From $51M-$53M To $49.5M-$50.5M vs $52.03M Est.

Author: Benzinga Newsdesk | November 20, 2023 04:17pm

Posted In: RCEL